ResearcherUniversity of MichiganActive in the last 2 years
Mariana T. Ruckert
Matched on ORCID iD 0000-0002-8282-4454; OpenAlex author ID A5010498295. Sources: OpenAlex.
Their work
- Papers
- 7
- Trials
- 0
- Grants
- 0
- Labs led
- 0
- Collaborators
- 22
2019: 1 paper · 2020: none · 2021: none · 2022: 2 papers · 2023: 1 paper · 2024: none · 2025: 2 papers · 2026: 1 paper
Papers 7
- Asynchronous Evolution of Epithelium and Stroma Differentiates Precursor Lesions from Pancreatic Cancer. Co-author DOI 10.1158/2159-8290.cd-25-2001↗
- DUSP6 is upregulated in metastasis and influences migration and metabolism in pancreatic cancer cells. Co-author DOI 10.1038/s41598-025-12967-8↗
- Depletion of tumor-derived CXCL5 improves T cell infiltration and anti-PD-1 therapy response in an obese model of pancreatic cancer. Co-author DOI 10.1136/jitc-2024-010057↗
- SHP2 regulates adipose maintenance and adipocyte-pancreatic cancer cell crosstalk via PDHA1. Co-author DOI 10.1007/s12079-022-00691-1↗
- Synthetic adiponectin-receptor agonist, AdipoRon, induces glycolytic dependence in pancreatic cancer cells. Co-author DOI 10.1038/s41419-022-04572-8↗
- Correction: Synthetic adiponectin-receptor agonist, AdipoRon, induces glycolytic dependence in pancreatic cancer cells. Co-author DOI 10.1038/s41419-022-04615-0↗
- Protein tyrosine phosphatases: promising targets in pancreatic ductal adenocarcinoma. Co-author DOI 10.1007/s00018-019-03095-4↗
Closest collaborators
The 22 strongest of 22 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.
- Bailey A. Bye · 5 shared papers, 2022–2025 · strength 0.94
- Paper Depletion of tumor-derived CXCL5 improves T cell infiltration and anti-PD-1 therapy response in an obese model of pancr… DOI 10.1136/jitc-2024-010057↗
- Paper DUSP6 is upregulated in metastasis and influences migration and metabolism in pancreatic cancer cells. DOI 10.1038/s41598-025-12967-8↗
- Paper SHP2 regulates adipose maintenance and adipocyte-pancreatic cancer cell crosstalk via PDHA1. DOI 10.1007/s12079-022-00691-1↗
- Michael Nathan VanSaun · 5 shared papers, 2022–2025 · strength 0.94
- Paper Depletion of tumor-derived CXCL5 improves T cell infiltration and anti-PD-1 therapy response in an obese model of pancr… DOI 10.1136/jitc-2024-010057↗
- Paper DUSP6 is upregulated in metastasis and influences migration and metabolism in pancreatic cancer cells. DOI 10.1038/s41598-025-12967-8↗
- Paper SHP2 regulates adipose maintenance and adipocyte-pancreatic cancer cell crosstalk via PDHA1. DOI 10.1007/s12079-022-00691-1↗
- R. McKinnon Walsh · 4 shared papers, 2022–2025 · strength 0.76
- Paper Depletion of tumor-derived CXCL5 improves T cell infiltration and anti-PD-1 therapy response in an obese model of pancr… DOI 10.1136/jitc-2024-010057↗
- Paper DUSP6 is upregulated in metastasis and influences migration and metabolism in pancreatic cancer cells. DOI 10.1038/s41598-025-12967-8↗
- Paper Synthetic adiponectin-receptor agonist, AdipoRon, induces glycolytic dependence in pancreatic cancer cells. DOI 10.1038/s41419-022-04572-8↗
- Appolinaire A. Olou · 4 shared papers, 2022–2025 · strength 0.71
- Paper Depletion of tumor-derived CXCL5 improves T cell infiltration and anti-PD-1 therapy response in an obese model of pancr… DOI 10.1136/jitc-2024-010057↗
- Paper SHP2 regulates adipose maintenance and adipocyte-pancreatic cancer cell crosstalk via PDHA1. DOI 10.1007/s12079-022-00691-1↗
- Paper Synthetic adiponectin-receptor agonist, AdipoRon, induces glycolytic dependence in pancreatic cancer cells. DOI 10.1038/s41419-022-04572-8↗
- Marina Pasca di Magliano · 2 shared papers, 2025–2026 · strength 0.44
- Jiaqi Shi · 2 shared papers, 2025–2026 · strength 0.44
- Costas Andreas Lyssiotis · 2 shared papers, 2025–2026 · strength 0.44
- Filip Bednar · 2 shared papers, 2025–2026 · strength 0.44
- Vanessa S. Silveira · 2 shared papers, 2019–2025 · strength 0.37
- Sharon Manley · 2 shared papers, 2022 · strength 0.29
- Paper Synthetic adiponectin-receptor agonist, AdipoRon, induces glycolytic dependence in pancreatic cancer cells. DOI 10.1038/s41419-022-04572-8↗
- Paper Correction: Synthetic adiponectin-receptor agonist, AdipoRon, induces glycolytic dependence in pancreatic cancer cells. DOI 10.1038/s41419-022-04615-0↗
- Shrikant Anant · 2 shared papers, 2022 · strength 0.29
- Paper Synthetic adiponectin-receptor agonist, AdipoRon, induces glycolytic dependence in pancreatic cancer cells. DOI 10.1038/s41419-022-04572-8↗
- Paper Correction: Synthetic adiponectin-receptor agonist, AdipoRon, induces glycolytic dependence in pancreatic cancer cells. DOI 10.1038/s41419-022-04615-0↗
- Emily L. Lasse Opsahl · 1 shared paper, 2025 · strength 0.23
- Elana Judith Fertig · 1 shared paper, 2026 · strength 0.21
- Brian D. Griffith · 1 shared paper, 2026 · strength 0.21
- Eileen S. Carpenter · 1 shared paper, 2026 · strength 0.21
- Padma Kadiyala · 1 shared paper, 2026 · strength 0.21
- Julianne M. Szczepanski · 1 shared paper, 2026 · strength 0.21
- Ahmed M. Elhossiny · 1 shared paper, 2026 · strength 0.21
- Yaqing Zhang · 1 shared paper, 2026 · strength 0.21
- Anirban Maitra · 1 shared paper, 2026 · strength 0.21
- Timothy L. Frankel · 1 shared paper, 2026 · strength 0.21
- Prasad R. Dandawate · 1 shared paper, 2023 · strength 0.18
How to reach this person
A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.